Exploratory Reta stack
Tesamorelin and metabolic-receptor literature, collected for independent review.
Community-referenced selection · combination unvalidated
No supporting controlled human study of this exact combination was identified in our September 5, 2026 review. Safety and efficacy together are unestablished. Individual tesamorelin findings do not establish added visceral-fat reduction or improved body composition with this combination. Evidence from selected clinical populations cannot be generalized to these catalog vials.
Places tesamorelin's GHRH-analogue literature beside an independent metabolic-receptor record. Retatrutide is the only metabolic-receptor anchor in this collection. Each material remains a separate product record.
Published findings concern the stated study materials and models. They do not establish the exact catalog combination.
Individual product records, together for review.
1 vial
$120
PDL-RT3 is the catalog alias for a synthetic peptide analogue in the triple incretin-receptor research class. Its laboratory record identifies the underlying analyte separately, while the catalog material is supplied as a sealed vial of lyophilized powder for analytical research.
Lot documentation published
1 vial
$65
TESA is a synthetic 44-residue analogue of human growth hormone-releasing hormone, distinguished by an N-terminal trans-3-hexenoic acid modification. It belongs to the full-length GHRH analogue family and is supplied as a sealed vial of lyophilized powder for laboratory research.
Lot documentation published
One vial of each included product.
Individual value: $185Save $15
Ask about Reta + Tesamorelin
Contact us for current availability and lot documentation for the products in this selection.
Laboratory research only. Goal labels describe research themes, not promised outcomes or combined-use guidance. Each product is a separate catalog record. Not for human or veterinary use.